Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders

A method for delaying or ameliorating at least one symptom of pre-eclampsia or eclampsia in a subject diagnosed as having an increased risk for developing pre-eclampsia or eclampsia, wherein said subject is on or after the 20th week of pregnancy, said method comprising administering to said subject (i) a compound capable of decreasing soluble endoglin expression levels or soluble endoglin biological activity, wherein said compound is an antibody that specifically binds soluble endoglin, or a soluble endoglin antigen binding fragment thereof, or a growth factor that binds to soluble endoglin and (ii) a compound capable of decreasing sFlt-1 expression levels or sFlt-1 biological activity, wherein said compound is an antibody that specifically binds sFlt-1, or an sFlt-1 antigen binding fragment thereof, or a growth factor that binds to sFlt-1, wherein said at least one symptom is selected from the group consisting of a systolic blood pressure greater than 140 mmHg and a diastolic blood pressure greater than 90 mmHg after 20 weeks gestation;

• new onset proteinuria;
• greater than 300 mg of protein in a 24-hour urine collection;
• and a single random urine sample having a protein/creatinine ratio greater than 0.3, and wherein said administering is in an amount sufficient to delay or ameliorate at least one of said symptoms of pre-eclampsia or eclampsia in said subject, said subject having increased soluble endoglin or sFlt-1 polypeptide or nucleic acid expression levels of at least 10% relative to a normal reference sample or level.